BIX — Ellipsiz Income Statement
0.000.00%
Last trade - 00:00- SG$46.40m
- SG$4.29m
- SG$57.76m
- 38
- 78
- 88
- 81
Annual income statement for Ellipsiz, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | R2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 54.5 | 55.6 | 59.1 | 49.8 | 57.8 |
| Cost of Revenue | |||||
| Gross Profit | 12.1 | 12.1 | 11.7 | 10.6 | 12.2 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 53.6 | 52 | 59.2 | 53.6 | 57.3 |
| Operating Profit | 0.869 | 3.59 | -0.053 | -3.86 | 0.416 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 4.37 | 3.8 | 1.11 | -2.36 | 1.73 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3.74 | 3.19 | 0.698 | -2.89 | 1.05 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 3.05 | 2.75 | 2.05 | -3.84 | 3.63 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3.05 | 2.75 | 2.05 | -3.84 | 3.63 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.033 | 0.016 | 0.012 | 0.011 | 0.012 |
| Dividends per Share | |||||
| Special Dividends per Share |